An AI tool using echocardiograms accurately screens for cardiac amyloidosis, outperforming traditional detection methods.
Key Details
- 1AI model analyzes echocardiogram (ultrasound) images to screen for cardiac amyloidosis.
- 2Developed by Mayo Clinic and Ultromics; validated in a global, multi-ethnic cohort across 18 hospitals.
- 3Achieved 85% sensitivity and 93% specificity in detecting or ruling out cardiac amyloidosis.
- 4Outperformed existing clinical scoring systems for early diagnosis.
- 5FDA-cleared and already being implemented in multiple US hospitals.
Why It Matters
Early, accurate identification of cardiac amyloidosis is critical due to effective therapies available only at earlier disease stages. AI-based screening of routine cardiac ultrasound could substantially improve detection rates and patient outcomes, supporting broader integration of imaging AI in clinical care.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.